Skip to main content

© 2026 WEKU

NPR for Central and Eastern Kentucky

Support WEKU!

Play Live Radio

Next Up:

0:00

0:00

0:00 0:00

Available On Air Stations

Abdul El-Sayed, Michigan's Democratic Senate nominee, discusses the race

NPR | By Michel Martin

Published August 5, 2026 at 11:20 AM EDT

NPR's Michel Martin speaks with Senate candidate Dr. Abdul El-Sayed following the Michigan primary elections.

Copyright 2026 NPR

Michel Martin

Michel Martin is a host of Morning Edition.

See stories by Michel Martin

Support nonprofit, fact-based public service journalism

WEKU depends on support from those who view and listen to our content. There's no paywall here. Please support WEKU with your donation.

Contribute now

Related Content

NPR News

Pakistan's ruling party leads in Kashmir vote despite boycott call by banned group

The Associated Press

Candidates backed by twice-elected former Prime Minister Nawaz Sharif's Pakistan Muslim League-N party have won 24 of the 34 seats decided in the first two phases of voting, the election commission, said Wednesday.
NPR News

Under China's new 'unity' law, Tibetans fight to preserve language and culture

The Associated Press

A 73-year-old retired nurse's decision to learn to write Tibetan language offers a glimpse into how some embrace their language and cultural identity in Tibet.
NPR News

Progressive Abdul El-Sayed wins Michigan's Democratic primary for Senate

Maham Javaid

El-Sayed, an epidemiologist, backs Medicare for all and decries corporate money in politics. He beat Rep. Haley Stevens, whose supporters said she would have had a better chance in the fall.
Lexington/Richmond

As cyclosporiasis cases grow, some Kentucky customers turn to local produce

Lily Burris

Some produce providers are seeing growing interest in farmers' markets and other non-grocery store options for fruits and vegetables.
NPR News

U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech

Brittney Melton

The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.